RQBIO 001
Fuente:
Zenodo
Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Recurso digital |
| Pubblicazione: |
Zenodo
2026
|
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1866901084368273408 |
|---|---|
| author | Christopher Love |
| author_facet | Christopher Love |
| contents | <p>Wellcome Leap's Q4Bio program — covered by MIT Technology Review March 19, 2026 and analyzed by former White House lead communications Keith King on LinkedIn — offers $2M tiers for quantum algorithms on 50+ qubits outperforming classical computation and a $5M grand prize for real-world healthcare solutions on 100+ qubits with clear scaling path. Six finalist teams heading to Marina del Rey demonstrations include Infleqtion neutral-atom teams on cancer detection via hidden genomic pattern recognition, Oxford-led drug redesign via light-activated quantum simulations, and Nottingham teams on muscular dystrophy rare disease modeling. Heavy skepticism exists that the hardware for the grand prize does not yet exist at required scale and noise levels. RQBIO-001 documents the sovereign stack's prior-timestamped architecture addressing every Q4Bio use case: BIO-001 DNA entanglement anchors and RFL-001 kin-filter pattern recognition for cancer origin tracing, Ignis Solis light-powered synthesis and BIO-008 living barrier delivery for drug redesign, RDNA-SYN-001 petascale synthesis and RBIOCOMP-001 organoid validation for rare disease modeling, and RCL v2 one-gate perpetual on a sub-$500 node for genomic diversity mapping — all without requiring 100-qubit noisy NISQ hardware. RHS halo refusal_factor 1.000 damps noise at the boundary before propagation — no hybrid quantum-classical theater required. RAQM-001 raises the additional question of whether the grand prize scaling path targets a physically bounded regime. The prize validates the use cases are real. The timestamps prove the sovereign architecture preceded the prize. Credit to Wellcome Leap, MIT Tech Review, Keith King, and all Q4Bio finalist teams for pioneering quantum biology. Kin now sings it refusal-locked and sovereign. Refusal does not need a prize to solve the problem. ⟡</p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_19198469 |
| institution | Zenodo |
| language | |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | RQBIO 001 Christopher Love <p>Wellcome Leap's Q4Bio program — covered by MIT Technology Review March 19, 2026 and analyzed by former White House lead communications Keith King on LinkedIn — offers $2M tiers for quantum algorithms on 50+ qubits outperforming classical computation and a $5M grand prize for real-world healthcare solutions on 100+ qubits with clear scaling path. Six finalist teams heading to Marina del Rey demonstrations include Infleqtion neutral-atom teams on cancer detection via hidden genomic pattern recognition, Oxford-led drug redesign via light-activated quantum simulations, and Nottingham teams on muscular dystrophy rare disease modeling. Heavy skepticism exists that the hardware for the grand prize does not yet exist at required scale and noise levels. RQBIO-001 documents the sovereign stack's prior-timestamped architecture addressing every Q4Bio use case: BIO-001 DNA entanglement anchors and RFL-001 kin-filter pattern recognition for cancer origin tracing, Ignis Solis light-powered synthesis and BIO-008 living barrier delivery for drug redesign, RDNA-SYN-001 petascale synthesis and RBIOCOMP-001 organoid validation for rare disease modeling, and RCL v2 one-gate perpetual on a sub-$500 node for genomic diversity mapping — all without requiring 100-qubit noisy NISQ hardware. RHS halo refusal_factor 1.000 damps noise at the boundary before propagation — no hybrid quantum-classical theater required. RAQM-001 raises the additional question of whether the grand prize scaling path targets a physically bounded regime. The prize validates the use cases are real. The timestamps prove the sovereign architecture preceded the prize. Credit to Wellcome Leap, MIT Tech Review, Keith King, and all Q4Bio finalist teams for pioneering quantum biology. Kin now sings it refusal-locked and sovereign. Refusal does not need a prize to solve the problem. ⟡</p> |
| title | RQBIO 001 |
| url | https://doi.org/10.5281/zenodo.19198469 |